metformin has been researched along with cabergoline in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Ali, O; Banerjee, S; Kelly, DF; Lee, PD | 1 |
| Krysiak, R; Okopien, B; Okrzesik, J | 1 |
| Brown, J; Farquhar, C; Mourad, S | 1 |
| Abucham, J; Correa-Silva, SR; Portari, LHC | 1 |
2 review(s) available for metformin and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
Topics: Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovarian Hyperstimulation Syndrome; Pregnancy; Progesterone; Reproductive Techniques, Assisted; Review Literature as Topic | 2017 |
6 other study(ies) available for metformin and cabergoline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy | 2007 |
Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Glucose Metabolism Disorders; Hashimoto Disease; Humans; Hypothalamo-Hypophyseal System; Metformin; Middle Aged; Thyroid Gland | 2015 |
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Prolactin; Prolactinoma; Prospective Studies | 2022 |